Protocol to derive human trophoblast stem cells directly from primed pluripotent stem cells

Yanxing Wei; Lu Xiao; Lishi Ma; Zhijian Wang; Liping Huang; Huiying Li; Guangjin Pan; Stephen J. Lye; Yongli Shan

STAR Protocols (Sep 2022)

Protocol to derive human trophoblast stem cells directly from primed pluripotent stem cells

Yanxing Wei,
Lu Xiao,
Lishi Ma,
Zhijian Wang,
Liping Huang,
Huiying Li,
Guangjin Pan,
Stephen J. Lye,
Yongli Shan

Affiliations

Yanxing Wei: Placenta Research Group, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5T3H7, Canada; Key Laboratory of Functional Proteomics of Guangdong Province, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China; The First Clinical Medical School, Southern Medical University, Guangzhou 510515, China
Lu Xiao: Placenta Research Group, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
Lishi Ma: Placenta Research Group, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
Zhijian Wang: Placenta Research Group, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
Liping Huang: Placenta Research Group, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
Huiying Li: The First Clinical Medical School, Southern Medical University, Guangzhou 510515, China
Guangjin Pan: CAS Key Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China
Stephen J. Lye: Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5T3H7, Canada; Department of Obstetrics & Gynecology, University of Toronto, Toronto, ON M5G1L4, Canada; Department of Physiology, University of Toronto, Toronto, ON M5G1L4, Canada
Yongli Shan: Placenta Research Group, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; CAS Key Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China; Corresponding author

Journal volume & issue: Vol. 3, no. 3
p. 101638

Abstract

Read online

Summary: Human trophoblast stem cells (hTSCs) are useful for studying human placenta development and diseases, but primed human pluripotent stem cells (hPSCs) routinely cultured in most laboratories do not support hTSC derivation. Here, we present a protocol to derive hTSCs directly from primed hPSCs. This approach, containing two strategies either with or without bone morphogenetic protein 4 (BMP4), provides a simple and accessible tool for deriving hTSCs to study placenta development and disease modeling without ethical limitations or reprogramming process.For complete details on the use and execution of this protocol, please refer to Wei et al. (2021). : Publisher’s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics.

Published in STAR Protocols

ISSN: 2666-1667 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Science: Science (General)
Website: https://star-protocols.cell.com/

About the journal

Abstract

Keywords